CaffeineNCT06039358
Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects
A study testing Caffeine. and Cellulose. in people with Caffeine and Biomechanics, run by University of Vic - Central University of Catalonia at 1 site in Spain.
Trial summary
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Caffeine, Biomechanics, Fatigue
- What is being tested?
- Caffeine. and Cellulose.
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteSpain
- Study dates
- 6 Oct 2023to 23 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- An uninterrupted training time of at least 1 year in the subjects' regular exercise modality (either the person is still training or interrupted the training period during the last year, and with no more than 4 months of detraining).
- A good exercise technique of the assessed movement patterns (running, squatting, and jumping).
Who cannot join
- Not being 18-30 years old.
- Having any relevant medical condition.
- Pregnancy.
- Smoking.
- Regular medication consumption / Medication consumption the days before the sessions during the study.
- Other supplementation regular consumption / Other supplementation consumption during the study (excluding sports foods, provided that their goal and nutrients have the objective of substituting the ingestion of regular food (e.g., isotonic drinks, carbohydrates gels, protein powder...), without adding other components that may act as ergogenic substances).
- Habitual caffeine consumption of >25mg/day-0,99mg/kg/day.
Trial locations and contacts
1 site in 1 country.
Spain1 site
University of Vic - Central University of Catalonia.
Vic, Barcelona., 08500.
About this study
Official title: Influence of 6mg/kg of Caffeine Supplementation on the Technical Execution of General Movement Patterns Performed by Healthy Subjects, With and Without Neuromuscular Fatigue: a Randomized, Double-blind, Placebo-controlled, Crossover Trial
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. The beneficial effect of this substance on physical and cognitive performance has been identified in aerobic and anaerobic efforts, including aerobic and muscular endurance, power, or strength.
However, it seems that the benefits of caffeine are usually measured only by its effect on performance, while a comprehensive analysis of its impact on other aspects of the movement technique of the exercise is not considered. Therefore, although caffeine generates better performance, a null or negative effect may occur on technique execution. As such, some consequences might arise (e.g., an increase in injury risk or a decrease in energy efficiency).
Read more
The objective of this randomized controlled trial is to assess the influence of caffeine on certain biomechanical parameters of the technique of physical exercises in circumstances without fatigue and under neuromuscular fatigue. The study hypothesis is that caffeine generates modifications in the technical execution of certain movements in fatigued and unfatigued circumstances due to its physiological effects, which may be beneficial for performance and injury prevention.
The participants will have to attend 5 sessions (enrollment, familiarization, control, placebo, and caffeine), at least 7 days apart. In the last 3 sessions, different measurements will be done to their technique while jumping, squatting, and running, without fatigue and with it. Other data will be collected throughout the study to contextualize and analyze in more detail the obtained information.
Read the detailed description
A detailed description of the study can be found in the protocol uploaded with this registry entry.
- Conditions
- Caffeine, Biomechanics, Fatigue, Injuries, Physical Activity
- Being tested
- Caffeine., Cellulose.
- Keywords
- Ergogenic aids, Kinematics, Kinetics, Neuromuscular fatigue, Acute and chronic injuries, Jump, Squat, Running
- Medical subject headings
- Fatigue, Wounds and Injuries, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caffeine.Dietary supplement
Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Cellulose.Drug
Also called Placebo.
Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
| Study group | Role | What they receive |
|---|---|---|
| Control - caffeine - placebo. | Experimental | The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one. Receives: Dietary Supplement: Caffeine.; Drug: Cellulose. |
| Control - placebo - caffeine. | Experimental | The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one. Receives: Dietary Supplement: Caffeine.; Drug: Cellulose. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Knee flexion angle at the midstance while running.
Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Ankle dorsiflexion angle at the midstance while running.
Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Step rate while running.
Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Contact time while running.
Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Stride length while running.
Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Flight time while running.
Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Running performance modification.
Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Execution time while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Rate of force development while squatting, for the eccentric and the concentric phases of the movement.
Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Squatting performance modification.
Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.
Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.
Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Unweighting phase duration while jumping (jumping phase).
Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Braking phase duration while jumping (jumping phase).
Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Propulsive phase duration while jumping (jumping phase).
Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Relative peak power output while jumping (jumping phase).
Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Jumping performance modification.
Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Measured: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Secondary outcomes (2)
Supplementation identification.
Assessment of the participants' perception regarding the ingested substance. They will have to complete a questionnaire immediately before (1 hour post-supplementation) and after the assessed exercises, indicating what substance they believe that they have consumed, with the options "caffeine", "placebo", or "I don't know", as well as the reason why they have chosen that answer.
Measured: During the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Side effects.
Assessment of the participant's side effects related to caffeine consumption. In the morning of the day after the sessions, they will be requested to complete a questionnaire comprised of 8 questions with a yes/no answer, to evaluate the side effects of caffeine consumption during the hours after the sessions.
Measured: During the day after the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2023
- Study start6 Oct 2023
- Primary completion22 Dec 2023
- Study completion23 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CaffeineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The assessed sessions, which will be identical, will be the control, the caffeine, and the placebo ones. The last two sessions mentioned will be performed in a randomized order.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Vic - Central University of Catalonia
- Sponsor type
- University, hospital or other
- Collaborators
- Generalitat de Catalunya, European Union
- Responsible party
- Sponsor
- Investigators
- Arnau Baena Riera, MSc., Principal investigator, Sport, Exercise, and Human Movement (SEaHM), University of Vic - Central University of Catalonia.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06039358
- Sponsor's protocol ID
- CAFBIOM001
- Status last verified
- Aug 2025
- First submitted
- 1 Sep 2023
- Last updated
- 3 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of 6mg/kg of Caffeine Supplementation on the Technical Execution of General Movement Patterns Performed by Healthy Subjects, With and Without Neuromuscular Fatigue: a Randomized, Double-blind, Placebo-controlled, Crossover Trial
- ClinicalTrials.gov ID
- NCT06039358
- Acronym / sponsor ID
- CAFBIOM001
- Conditions
- Caffeine, Biomechanics, Fatigue, Injuries, Physical Activity
- Keywords
- Ergogenic aids, Kinematics, Kinetics, Neuromuscular fatigue, Acute and chronic injuries, Jump, Squat, Running
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- University of Vic - Central University of CataloniaUniversity, hospital or other
- Collaborators
- Generalitat de Catalunya, European Union
- Study start
- 6 Oct 2023 (actual)
- Primary completion
- 22 Dec 2023 (actual)
- Study completion
- 23 Dec 2023 (actual)
- First posted
- 15 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. The beneficial effect of this substance on physical and cognitive performance has been identified in aerobic and anaerobic efforts, including aerobic and muscular endurance, power, or strength.
However, it seems that the benefits of caffeine are usually measured only by its effect on performance, while a comprehensive analysis of its impact on other aspects of the movement technique of the exercise is not considered. Therefore, although caffeine generates better performance, a null or negative effect may occur on technique execution. As such, some consequences might arise (e.g., an increase in injury risk or a decrease in energy efficiency).
The objective of this randomized controlled trial is to assess the influence of caffeine on certain biomechanical parameters of the technique of physical exercises in circumstances without fatigue and under neuromuscular fatigue. The study hypothesis is that caffeine generates modifications in the technical execution of certain movements in fatigued and unfatigued circumstances due to its physiological effects, which may be beneficial for performance and injury prevention.
The participants will have to attend 5 sessions (enrollment, familiarization, control, placebo, and caffeine), at least 7 days apart. In the last 3 sessions, different measurements will be done to their technique while jumping, squatting, and running, without fatigue and with it. Other data will be collected throughout the study to contextualize and analyze in more detail the obtained information.
Detailed description
A detailed description of the study can be found in the protocol uploaded with this registry entry.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The assessed sessions, which will be identical, will be the control, the caffeine, and the placebo ones. The last two sessions mentioned will be performed in a randomized order.
| Arm | Type | Receives |
|---|---|---|
| Control - caffeine - placebo. | Experimental | Dietary Supplement: Caffeine., Drug: Cellulose.The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one. |
| Control - placebo - caffeine. | Experimental | Dietary Supplement: Caffeine., Drug: Cellulose.The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- An uninterrupted training time of at least 1 year in the subjects' regular exercise modality (either the person is still training or interrupted the training period during the last year, and with no more than 4 months of detraining).
- A good exercise technique of the assessed movement patterns (running, squatting, and jumping).
Key exclusion criteria (7 listed)
- Not being 18-30 years old.
- Having any relevant medical condition.
- Pregnancy.
- Smoking.
- Regular medication consumption / Medication consumption the days before the sessions during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caffeine.Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm). | Dietary supplement | Control - caffeine - placebo., Control - placebo - caffeine. |
| Cellulose.Also: Placebo.Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm). | Drug | Control - caffeine - placebo., Control - placebo - caffeine. |
Primary outcome
Knee flexion angle at the midstance while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Ankle dorsiflexion angle at the midstance while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Step rate while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Contact time while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Stride length while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Flight time while running.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Running performance modification.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch.
Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Execution time while squatting, for the eccentric and the concentric phases of the movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Rate of force development while squatting, for the eccentric and the concentric phases of the movement.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Squatting performance modification.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.
Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.
Unweighting phase duration while jumping (jumping phase).
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Braking phase duration while jumping (jumping phase).
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Propulsive phase duration while jumping (jumping phase).
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Relative peak power output while jumping (jumping phase).
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
Jumping performance modification.
Time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates.
2 secondary outcomes
Supplementation identification.
Time frame: During the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Side effects.
Time frame: During the day after the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Caffeine
RecruitingPhase 4
Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.
Vibration Therapy, Caffeine
Active, not recruiting
The REVIVE-PEEP Trial: Positive End-expiratory Pressure Versus Sham Valve/Zero End-expiratory Pressure in Cardiopulmonary Resuscitation During Manual Ventilation to Improve Neurological Outcomes at Discharge in Adult Patients Suffering an Out-of-hospital Cardiac Arrest
Cardiac Arrest, Out-Of-Hospital
Recruiting
The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation
Healthy
Active, not recruitingPhase 4
A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising
Exercise
Not yet recruitingPhase 2
CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)
Meconium Aspiration Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arnau Baena Riera, MSc. principal investigator
Sport, Exercise, and Human Movement (SEaHM), University of Vic - Central University of Catalonia.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine. and Cellulose. in people with Caffeine and Biomechanics, run by University of Vic - Central University of Catalonia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knee flexion angle at the midstance while running. (time frame: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.). The study lists 21 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.